Company Overview

Hologic, Inc. is a global medical technology company focused on improving women’s health through diagnostic, medical imaging, and surgical products. The company operates primarily within the medical devices, diagnostics, and healthcare technology industries, with a strong emphasis on breast health, gynecologic health, and molecular diagnostics. Its core customers include hospitals, diagnostic laboratories, imaging centers, and healthcare providers serving women across preventive screening, diagnosis, and treatment.

Founded in 1985, Hologic evolved from a small diagnostic testing firm into a diversified healthcare company through internal innovation and a series of acquisitions. A defining milestone in its history was the acquisition of Gen-Probe Incorporated in 2012, which significantly expanded its molecular diagnostics capabilities and reshaped the company’s revenue base. Over time, Hologic has positioned itself as a market leader in breast imaging and women’s health diagnostics, supported by proprietary technologies, a large installed base, and recurring revenue from consumables and service contracts.

Business Operations

Hologic operates through three primary business segments: Diagnostics, Breast Health, and Surgical. The Diagnostics segment generates revenue through molecular diagnostic assays, instruments, and laboratory automation systems, with recurring revenue driven by test volumes and consumables. The Breast Health segment includes digital mammography systems, breast biopsy solutions, and related software, benefiting from long-term service agreements and equipment placements. The Surgical segment focuses on minimally invasive gynecologic surgical products, including tissue removal and ablation technologies.

The company maintains both domestic and international operations, with manufacturing, research and development, and commercial activities spread across multiple regions. Hologic controls proprietary platforms in molecular diagnostics and imaging, supported by a robust intellectual property portfolio. Its operations also include several wholly owned subsidiaries that support manufacturing, distribution, and regional sales, with no material joint ventures publicly disclosed as core to revenue generation.

Strategic Position & Investments

Hologic’s strategy centers on sustainable growth in women’s health through innovation, operational efficiency, and selective acquisitions. The company prioritizes expanding its installed base of diagnostic and imaging systems, which drives recurring revenue from consumables, service, and software. Growth initiatives include product enhancements in molecular diagnostics, automation solutions for laboratories, and advanced imaging technologies designed to improve clinical outcomes and workflow efficiency.

Historically, Hologic has pursued targeted acquisitions to strengthen its technology portfolio and market position, including Gen-Probe Incorporated and Diagenode S.A., which expanded its diagnostics and sample preparation capabilities. The company continues to invest in research and development focused on emerging diagnostic assays, minimally invasive surgical solutions, and digital health tools that complement its core platforms.

Geographic Footprint

Hologic is headquartered in North America, with its corporate headquarters located in Marlborough, Massachusetts, United States. The company has a significant presence across Europe, Asia-Pacific, and Latin America, serving customers in over 100 countries through direct sales organizations and distributors. International markets represent a substantial portion of revenue, particularly in diagnostics and breast imaging.

Manufacturing and research facilities are strategically located in the United States, Europe, and Asia, enabling global supply chain resilience and regional customization. Hologic’s international footprint supports both developed and emerging healthcare markets, with investments aimed at expanding access to women’s health diagnostics and imaging technologies worldwide.

Leadership & Governance

Hologic is led by an experienced executive team with a strategic focus on operational discipline, innovation, and shareholder value creation. The leadership emphasizes evidence-based medicine, quality, and long-term investment in women’s health as core elements of the company’s governance and strategic vision.

Key executives include:

• Stephen P. MacMillan – Chairman, President, and Chief Executive Officer
• Karleen Oberton – Chief Financial Officer
• Jennifer A. Schneiders – Chief Human Resources Officer
• Pete Valenti – Division President, Diagnostics
• David Harding – Division President, Surgical
• Erik Anderson – Division President, Breast Health